Parents
Sign in to add mentor| Allen J. Dozor | fellowship/program director | 1994 | Maria Fareri Children's Hospital at Westchester Medical Center |
| Allen J. Dozor | fellowship/program director | 1994 | Maria Fareri Children's Hospital at Westchester Medical Center |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pavord ID, Rabe KF, Israel E, et al. (2024) Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma. The Journal of Allergy and Clinical Immunology. in Practice |
| Bacharier LB, Pavord ID, Maspero JF, et al. (2024) Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma. The Journal of Allergy and Clinical Immunology |
| Bacharier LB, Guilbert TW, Katelaris CH, et al. (2023) Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study. The Journal of Allergy and Clinical Immunology. in Practice |
| Corren J, Hanania NA, Busse WW, et al. (2023) Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clinical and Experimental Allergy : Journal of the British Society For Allergy and Clinical Immunology. 53: 1020-1030 |
| Bachert C, Laidlaw TM, Cho SH, et al. (2023) Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results. The Annals of Otology, Rhinology, and Laryngology. 34894231176334 |
| Jackson DJ, Bacharier LB, Phipatanakul W, et al. (2023) Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology |
| Canonica GW, Bourdin A, Peters AT, et al. (2022) Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. The Journal of Allergy and Clinical Immunology. in Practice |
| Bacharier LB, Maspero JF, Katelaris CH, et al. (2021) Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. The New England Journal of Medicine. 385: 2230-2240 |
| Wechsler ME, Ruddy MK, Pavord ID, et al. (2021) Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. The New England Journal of Medicine. 385: 1656-1668 |
| Wechsler ME, Ford LB, Maspero JF, et al. (2021) Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. The Lancet. Respiratory Medicine |